Holen Sie sich die Stockscreener-App
3.36
2.55%
0.07
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Q4 Beat And AI Clinical Progress - simplywall.st
Recursion Pharmaceuticals and Applied Digital shares fall after Nvidia exits stakes - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells $94,798.30 in Stock - MarketBeat
What makes Recursion Pharmaceuticals (RXRX) so attractive - MSN
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1‑Year Share Slump Accurately - Yahoo Finance
A Look At Recursion Pharmaceuticals (RXRX) Valuation After AI Milestone And Improved Quarterly Results - Yahoo Finance
Recursion’s First AI Clinical Proof Links Pipeline Progress With Valuation Gap - Yahoo Finance
What Makes Recursion Pharmaceuticals (RXRX) So Attractive - Insider Monkey
Recursion rises on new data for asset for polyps - MSN
Measuring the AI Bubble - Pharmaceutical Executive
11 Most Popular AI Penny Stocks to Buy Now - Insider Monkey
Can This AI Stock Bounce Back in 2026? - Yahoo Finance
Day Trade: Why retail investors pile into Recursion Pharmaceuticals Inc. stockTrade Analysis Summary & Community Supported Trade Ideas - Naître et grandir
symbol__ Stock Quote Price and Forecast - CNN
10 Low Risk Penny Stocks to Buy Now - Insider Monkey
Recursion Pharmaceuticals’ Earnings Call Highlights AI Momentum - TipRanks
BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating - Insider Monkey
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Earnings Jump And New Equity Offering Plans - Sahm
Recursion Pharmaceuticals (RXRX) Is Down 6.1% After Insider Sale And New ATM Equity ProgramHas The Bull Case Changed? - Sahm
ARK Investment Management LLC Purchases 556,868 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. $RXRX Stake Cut by Amova Asset Management Americas Inc. - MarketBeat
Top Recursion Insider Quietly Unloads a Major Stake in the Company - TipRanks
RECURSION PHARMACEUTICALS Director Sells 170,000 Shares - TradingView
Rafferty Asset Management LLC Purchases 394,022 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
DNB Asset Management AS Purchases New Position in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Uncovering a Potential 84.97% Upside in Biotech - DirectorsTalk Interviews
Recursion: Nvidia Sells Out, Collaboration Still Alive, Data Ahead (NASDAQ:RXRX) - Seeking Alpha
RXRX: Integrated platform, strong partnerships, and disciplined pipeline drive innovation and growth - TradingView
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Vanguard Group Inc. Purchases 3,708,975 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals Stock Hits Day Low of $3.33 Amid Price Pressure - Markets Mojo
Assessing Recursion Pharmaceuticals (RXRX) After A 51% One Year Share Price Decline - Sahm
Recursion’s REC-4881 Milestone And Cash Runway Shift Risk Reward Profile - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Recursion’s First Clinical Signal And Sanofi Milestone Test AI Drug Thesis - simplywall.st
Recursion Pharmaceuticals : 2025 Shareholder Letter and Business Overview - marketscreener.com
How Investors May Respond To Recursion Pharmaceuticals (RXRX) Extending Cash Runway With New Equity Programs - simplywall.st
Recursion Pharmaceuticals Opens with 11.05% Gain Despite Recent Declines - Markets Mojo
Recursion Pharmaceuticals (RXRX) hits clinical milestones as 2025 revenue grows to $74.7M - MSN
Recursion Pharmaceuticals (RXRX) Hits Clinical Milestones as 2025 Revenue Grows to $74.7M - Yahoo Finance
Recursion Pharmaceuticals' (RXRX) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2025 Earnings Call Transcript - Insider Monkey
BofA Maintains Neutral on Recursion Pharmaceuticals (RXRX) Feb 25, 2026 - Meyka
Recursion Pharmaceuticals Q3 Loss Deepens Narrative Of Heavy Spending Over Limited US$5.2m Revenue - simplywall.st
Recursion Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:RXRX) 2026-02-25 - Seeking Alpha
Recursion Pharmaceuticals: Q4 Earnings Snapshot - theheraldreview.com
Recursion Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
RXRX Showcased at NVIDIA’s GTC Conference as AI Labs Collaborate - timothysykes.com
Recursion Pharmaceuticals (RXRX) Stock Surges After Beating Q4 EPS and Revenue Estimates - MEXC
Recursion Pharmaceuticals Q4: Why My December Buy Call Was Too Optimistic (NASDAQ:RXRX) - Seeking Alpha
BofA cuts Recursion Pharmaceuticals stock price target on launch timing - Investing.com
Recursion (RXRX) Q4 2025 Earnings Call Transcript - AOL.com
Recursion Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Recursion stock jumps after solid Q4 beat (RXRX:NASDAQ) - Seeking Alpha
Recursion’s AI-Enabled Drug Discovery Wins Spotlight at NVIDIA’s Conference - timothysykes.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Announces Earnings Results - MarketBeat
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up - The Globe and Mail
What's Behind The Jump In Recursion Pharmaceuticals Stock? - Benzinga
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up Following Better-Than-Expected Earnings - MarketBeat
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Recursion Pharmaceuticals Receives Spotlight with AI-driven Innovations at NVIDIA’s GTC - StocksToTrade
Recursion Q4 2025 slides: AI platform delivers first clinical proof-of-concept - Investing.com UK
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):